

March, 16, 2009 | Indianapolis, IN

Press Release



A corporate news update from your laboratory partner

DCL Medical Laboratories introduces Reveal Cx™

Breakthrough diagnostic test in risk assessment for cervical cancer assists physicians in providing individualized care

DCL is pleased to announce the introduction of the Reveal Cx™ test for the detection of 3q26 chromosomal gain in cervical cytology. This revolutionary test to assist in the evaluation of cervical cancer screening can help physicians provide more individualized care for their patients. DCL is the first laboratory in the Midwest to perform this test.

“We are very excited to provide the next step in the cervical cancer screening process,” said Carol Eisenhut, M.D., DCL Medical Director. “This new tool can enable clinicians to differentiate patients by risk level based on actual chromosomal changes that are indicators of progression risk for an individual.”

The 3q26 biomarker has been demonstrated in clinical studies to be related to chromosomal abnormalities in cervical cells consistent with increased risk of progression to abnormal cellular changes and cervical cancer. It is widely accepted that persistent high-risk Human Papilloma Virus (HPV) infection leads to genetic changes and chromosomal abnormalities that may evolve into cervical cancer. However, only a small number of patients progress to advanced stages.

One of the earliest chromosomal abnormalities detected in HPV-infected cervical cells is over-expression of chromosomal region 3q26. The Reveal Cx™ test is a Fluorescent in-situ hybridization test specifically targeting the 3q26 region.

Reveal Cx™ provides insight into which patients have cellular changes consistent with increased risk for progression and helps physicians in the development of more individualized patient care. The use of this test may allow physicians to differentiate earlier which patients will likely progress and which are not likely to progress to carcinoma.

Reveal Cx™ is a conventional fluorescence in-situ hybridization test and is expected to be a covered benefit by most health insurance companies.

About DCL Medical Laboratories

DCL Medical Laboratories, founded in 1984, has expanded from a fine needle biopsy clinic and cytology laboratory to a full-service regional laboratory with operations across the Midwest including specialty testing in molecular diagnostics.

DCL also provides anatomic pathology services in global clinical trials for both pharmaceutical and medical device companies in partnership with the world's largest central laboratories and clinical research organizations. DCL is committed to being a preferred medical laboratory partner providing nationally recognized diagnostic services in women's health.

From its founding, DCL has maintained a personal approach to delivering innovative and consultative pathology services that empower clients and improve lives. DCL is a private company with principal equity holdings by Thompson Street Capital Partners in St. Louis. For more information about DCL Medical Laboratories, visit www.dcla.com.

mspr128v2(7.20.09)